ARCHIVES

ODAC Rejects Amsacrine NDA, Renews Idarubicin

This article is from The Cancer Letter archive.

Vol. 16 No. 35 | September 14, 1990

Download PDF Visit The Full Archive

Related Articles

Phase III Study: Rituxan Improved PFS By 79% In Advanced Follicular Lymphoma

December 31, 2010

Women’s Health Trial RFPs Issued; Three Clinical Centers Sought

April 12, 1991

In Vote Against Tarceva As Maintenance, ODAC Seeks Stronger Survival Benefit

December 18, 2009

Oncology Faces Cuts In CMS Revamp Of Physician Payments Under Part B.

July 10, 2009

Cancer Congress Program Developed

June 27, 1980

NCI, Groups Disagree Over repayment, McIntyre: NCA Could Examine Relationship of Groups To NCI

December 9, 1994